<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146285">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893086</url>
  </required_header>
  <id_info>
    <org_study_id>KNC13-029</org_study_id>
    <nct_id>NCT01893086</nct_id>
  </id_info>
  <brief_title>The Effect on Risk-reducing Salpingectomy in Hysterectomy on Ovarian Reserve</brief_title>
  <official_title>The Effect on Risk-reducing Salpingectomy in Laparoscopic Hysterectomy on Ovarian Reserve: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, many gynecologic oncologists proposed that surgeons should consider risk-reducing
      salpingectomy (RRS) to prevent ovarian cancer for all patients undergoing hysterectomy for
      benign disease. However, the safety and the consequences regarding ovarian function after
      RSS have not yet to be established. Therefore, the aim of this randomized controlled study
      is compare the ovarian reserve via anti-Müllerian hormone (AMH) between laparoscopic
      hysterectomy (LH) alone and LH combined with RSS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ovarian reserve</measure>
    <time_frame>3 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ovarian reserve was determined by anti-Müllerian hormone (AMH)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Benign Uterine Disease</condition>
  <arm_group>
    <arm_group_label>LH alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LH, laparoscopic hysterectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LH with RSS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LH, laparoscopic hysterectomy; RSS, risk-reducing salpingectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LH</intervention_name>
    <arm_group_label>LH alone</arm_group_label>
    <arm_group_label>LH with RSS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RSS</intervention_name>
    <arm_group_label>LH with RSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with an age ≥18 years and less than 52 years

          -  women who scheduled for laparoscopic hysterectomy with planed preservation of both
             ovaries for a supposed benign gynecologic condition

          -  non-menopausal women

          -  women who were appropriated medical status for laparoscopic surgery (American Society
             of Anesthesiologists Physical Status classification 1 or 2)

        Exclusion Criteria:

          -  any ovarian mass with planed ovarian surgery; menopausal state; history of prior
             salpingectomy

          -  pregnancy at the time of presentation; or an inability to understand and provide
             written informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taejong Song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA Gangnam Medical Center, Seoul, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taejong Song, M.D.</last_name>
    <phone>+82-10-4035-8405</phone>
    <email>taejong.song@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Gangnam Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-081</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taejong Song, M.D.</last_name>
      <phone>+81-10-4035-8405</phone>
      <email>taejong.song@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Taejong Song, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 5, 2013</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Taejong Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
